Skip to main content
SpringerLink
Log in

Pyridoxal isonicotinoyl hydrazone (PIH) prevents copper-mediated in vitro free radical formation

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Pyridoxal isonicotinoyl hydrazone (PIH) is an iron chelator with antioxidant activity, low toxicity and is useful in the experimental treatment of iron-overload diseases. Previous studies on x-ray diffraction have revealed that PIH also forms a complex with Cu(II). Since the main drug of choice for the treatment of Wilson's disease, d-penicillamine, causes a series of side effects, there is an urgent need for the development of alternative copper chelating agents for clinical use. These chelators must also have antioxidant activity because oxidative stress is associated with brain and liver copper-overload. In this work we tested the ability of PIH to prevent in vitro free radical formation mediated by Cu(II), ascorbate and dissolved O2. Degradation of 2-deoxyribose mediated by 10 µM Cu(II) and 3 mM ascorbate was fully inhibited by 10 µM PIH (I50 = 6 µM) or 20 µM d-penicillamine (I50 = 10 µM). The antioxidant efficiency of PIH remained unchanged with increasing concentrations (from 1 to 15 mM) of the hydroxyl radical detector molecule, 2-deoxyribose, indicating that PIH does not act as a hydroxyl scavenger. On the other hand, the efficiency of PIH (against copper-mediated 2-deoxyribose degradation and ascorbate oxidation) was inversely proportional to the Cu(II) concentration, suggesting a competition between PIH and ascorbate for complexation with Cu(II). An almost full inhibitory effect by PIH was observed when the ratio PIH:copper was 1:1. A similar result was obtained with the measurement of copper plus ascorbate-mediated O2 uptake. Moreover, spectral studies of the copper and PIH interaction showed a peak at 455 nm and also indicated the formation of a stable Cu(II) complex with PIH with a 1:1 ratio. These data demonstrated that PIH prevents hydroxyl radical formation and oxidative damage to 2-deoxyribose by forming a complex with Cu(II) that is not reactive with ascorbate (first step of the reactions leading to hydroxyl radical formation from Cu(II), ascorbate and O2) and does not participate in Haber–Weiss reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schulman HM, Hermes-Lima M, Wang EM, Ponka P: In vitro antioxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone and some of its analogs. Redox Rep 1: 373–378, 1995

    Google Scholar 

  2. Hermes-Lima M, Nagy E, Ponka P, Schulman HM: The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against.OH-mediated strand breaks. Free Radic Biol Med 25: 875–880, 1998

    Google Scholar 

  3. Hermes-Lima M, Santos NCF, Yan J, Andrews M, Schulman HM, Ponka P: EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on.OH formation by the Fenton reaction. Biochim Biophys Acta 1426: 475–482, 1999

    Google Scholar 

  4. Hermes-Lima M, Ponka P, Schulman HM: The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate. Biochim Biophys Acta 1523: 154–160, 2000

    Google Scholar 

  5. Brittenham GM: Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration. Ann NY Acad Sci 612: 315–326, 1990

    Google Scholar 

  6. Richardson DR, Ponka P: Pyridoxal isonicotinoyl hydrazone and its analogues: Potential orally effective iron chelating agents for the treatment of iron overload disease. J Lab Clin Med 131: 306–314, 1998

    Google Scholar 

  7. Richardson DR, Ponka P: Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am J Hematol 58: 299–305, 1998

    Google Scholar 

  8. Webb J, Vitolo ML: Pyridoxal isonicotinoyl hydrazone (PIH): A promising new iron chelator. Birth Defects Orig Art Ser 23: 63–70, 1988

    Google Scholar 

  9. Brewer GJ: Practical recommendations and new therapies for Wilson's disease. Drugs 50: 240–249, 1995

    Google Scholar 

  10. Cuthbert J: Wilson's disease. Update of a systemic disorder with protean manifestations. Gastroenterol Clin North Am 27: 655–681, 1998

    Google Scholar 

  11. Schaefer M, Roelofsen H, Wolters H, Hofmann WJ, Muller M, Kuipers F, Stremmel W, Vonk RJ: Localization of the Wilson's disease protein in human liver. Gastroenterology 117: 1380–1385, 1999

    Google Scholar 

  12. Shimizu N, Yamaguchi Y, Aoki T: Treatment and management of Wilson's disease. Pediatr Int 41: 419–422, 1999

    Google Scholar 

  13. Gu M, Cooper JM, Butler P, Walker AP, Mistry PK, Dooley JS, Schapira AH: Oxidative-phosphorylation defects in liver of patients with Wilson's disease. Lancet 356: 469–474, 2000

    Google Scholar 

  14. Ogihara H, Ogihara T, Miki M, Yasuda H, Mino M: Plasma copper and antioxidant status in Wilson's disease. Pediatr Res 37: 219–226, 1995

    Google Scholar 

  15. Mansouri A, Gaou L, Fromenty B, Berson A, Letteron P, Degott C, Erlinger S, Pessayre D: Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. Gastroenterology 113: 599–605, 1997

    Google Scholar 

  16. Rui M, Suzuki KT: Copper in plasma reflects its status and subsequent toxicity in the liver of LEC rats. Res Commun Mol Pathol Pharmacol 98: 335–346, 1997

    Google Scholar 

  17. Nair J, Carmichael PL, Fernando RC, Phillips DH, Strain AJ, Bartsch H: Lipid peroxidation-induced etheno-DNA adducts in the liver of patients with the genetic metal storage disorders Wilson's disease and primary hemochromatosis. Cancer Epidemiol Biomarkers Prev 7: 435–440, 1998

    Google Scholar 

  18. Ntoso KA, Tomaszewski JE, Jimenez AS, Neilson EG: Penicillamine-induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: Successful treatment of two patients and a review of the literature. Am J Kidney Dis 8: 159–163, 1986

    Google Scholar 

  19. Huang CC, Chu NS: Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease. Eur Neurol 39: 32–37, 1998

    Google Scholar 

  20. An J, Hsie AW: Effects of an inhibitor and a mimic of superoxide dismutase on bleomycin mutagenesis in Chinese hamster ovary cells. Mutat Res 270: 167–175, 1992

    Google Scholar 

  21. Cohen NL, Keen CL, Lonnerdal B, Hurley LS: The effect of copper supplementation on the teratogenic effects of triethylenetetramine in rats. Drug Nutr Interact 2: 203–210, 1983

    Google Scholar 

  22. Tanaka H, Inomata K, Arima M: Teratogenic effects of triethylene tetramine dihydrochloride on the mouse brain. J Nutr Sci Vitaminol (Tokyo) 39: 177–188, 1993

    Google Scholar 

  23. Rao TR, Singh G: X-ray diffraction study of copper (II) complexes of pyridoxal isonicotinoyl hydrazone. Cryst Res Technol 24: 169–172, 1989

    Google Scholar 

  24. Richardson DR: Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: Effects of complexation with copper(II), gallium(III), and iron(III) on their antiproliferative activities. Antimicrob Agents Chemother 41: 2061–2063, 1997

    Google Scholar 

  25. Ponka P, Richardson D, Baker E, Schulman HM, Edward JT: Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim Biophys Acta 967: 122–129, 1988

    Google Scholar 

  26. Souron JP, Quarton M, Robert F, Lyubchova A, Cossebarbi A, Doucet JP: Pyridoxal isonicotinoyl hydrazone (PIH), a synthetic ion-chelating agent. Acta Crystalogr C 51: 2179–2182, 1995

    Google Scholar 

  27. Lopes GKB, Schulman HM, Hermes-Lima M: Polyphenol tannic acid inhibits hydroxyl radical formation from Fenton reaction by complexing ferrous ions. Biochim Biophys Acta 1472: 142–152, 1999

    Google Scholar 

  28. Hermes-Lima M, Wang EM, Schulman HM, Storey KB, Ponka P: Deoxyribose degradation catalyzed by Fe(III) EDTA: Kinetic aspects and potential usefulness for submicromolar iron measurements. Mol Cell Biochem 137: 65–73, 1994

    Google Scholar 

  29. Klein SM, Cohen G, Cederbaum AI: Production of formaldehyde during metabolism of dimethyl sulfoxide by hydroxyl radical generating system. Biochemistry 20: 6006–6012, 1981

    Google Scholar 

  30. Biaglow JE, Manevich Y, Uckun F, Held KD: Quantitation of hydroxyl radicals produced by radiation and copper-linked oxidation of ascorbate by 2-deoxy-D-ribose method. Free Radic Biol Med 22: 1129–1138, 1997

    Google Scholar 

  31. Hayakawa K, Hayashi Y: Detection of a complex intermediate in the oxidation of ascorbic acid by the copper (II) ion. J Nutr Sci Vitaminol (Tokyo) 23: 395–401, 1977

    Google Scholar 

  32. Beuttner GR, Jurkiewicz BA: Ascorbate radical: A valuable marker of oxidative stress. In: A.E. Favier, J. Cadet, B. Kalyanaraman, M. Fontecave, J.L. Pierre (eds). Analysis of Free Radicals in Biological Systems. Birkhäuser Verlag, Basel, Switzerland, 1995, pp 145–164

    Google Scholar 

  33. Bijloo GJ, van der Goot H, Bast A, Timmerman H: Copper complexes of 1,10-phenanthroline and related compounds as superoxide dismutase mimetics. J Inorg Biochem 40: 237–244, 1990

    Google Scholar 

  34. dos Santos MLP, Faljoni-Alário A, Mangrich AS, Ferreira AMD: Antioxidant and pro-oxidant properties of some di-Schiff base copper(II) complexes. J Inorg Biochem 71: 71–78, 1998

    Google Scholar 

  35. Rupp H, Weser U: Copper(I) and copper(II) in complexes of biochemical significance studied by X-ray photoelectron spectroscopy. Biochim Biophys Acta 446: 151–165, 1976

    Google Scholar 

  36. DM Van Reyk, Dean RT: The iron-selective chelator desferal can reduce chelated copper. Free Radic Res 24: 55–60, 1996

    Google Scholar 

  37. Gergely A, Sovago I: Complexes of sulfur-containing ligands. I. Factors influencing complex formation between D-penicillamine and copper (II) ion. Bioinorg Chem 9: 47–60, 1978

    Google Scholar 

  38. Laurie SH, Prime DM: The formation and nature of the mixed valence copper-D-penicillamine-chloride cluster in aqueous solution and its relevance to the treatment of Wilson's disease. J Inorg Biochem 11: 229–39, 1979

    Google Scholar 

  39. Gonçalves MS: Determinação da capacidade do piridoxal isonicotinoil hidrazona (PIH) de complexar íons cobre e prevenir a formação de radicais livres. M.Sc. Thesis. Universidade de Brasília, Brazil, 1999

    Google Scholar 

  40. Gunther MR, Hanna PM, Mason RP, Cohen MS: Hydroxyl radical formation from cuprous ion and hydrogen peroxide: A spin-trapping study. Arch Biochem Biophys 316: 515–522, 1995

    Google Scholar 

  41. Starkebaum G, Root RK: D-penicillamine: Analysis of the mechanism of copper-catalyzed hydrogen peroxide generation. J Immunol 134: 3371–3378, 1985

    Google Scholar 

  42. Yamanaka H, Hakoda M, Kamatani N, Kashiwazaki S, Carson DA: Formation of DNA strand breaks by D-penicillamine and bucillamine in human lymphocytes. Immunopharmacology 26: 113–118, 1993

    Google Scholar 

  43. Monig J, Asmus KD, Forni LG, Willson RL: On the reaction of molecular oxygen with thiyl radicals: A re-examination. Int J Radiat Biol Relat Stud Phys Chem Med 52: 589–602, 1987

    Google Scholar 

  44. Schoneich C, Bonifacic M, Asmus KD: Reversible H-atom abstraction from alcohols by thiyl radicals: Determination of absolute rate constants by pulse radiolysis. Free Radic Res Commun 6: 393–405, 1989

    Google Scholar 

  45. Sookvanichsilp N, Nakornchai S, Weerapradist W: Toxicological study of pyridoxal isonicotinoyl hydrazone: Acute and subchronic toxicity. Drug Chem Toxicol 14: 395–403, 1991

    Google Scholar 

  46. Bhattacharya M, Ponka P, Hardy P, Hanna N, Varma DR, Lachapelle P, Chemtob S: Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone. Free Radic Biol Med 22: 11–16, 1997

    Google Scholar 

  47. Brooks SPJ: A simple computer program with statistical tests for the analysis of enzyme kinetics. Biotechniques 13: 906–911, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oxyradical Research Group, Departamento de Biologia Celular, Universidade de Brasília, Brasília, DF 70910-900, Brazil

    Marcelo Hermes-Lima, Márcia S. Gonçalves & Roberto G. Andrade Jr.

Authors
  1. Marcelo Hermes-Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Márcia S. Gonçalves
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto G. Andrade Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcelo Hermes-Lima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hermes-Lima, M., Gonçalves, M.S. & Andrade, R.G. Pyridoxal isonicotinoyl hydrazone (PIH) prevents copper-mediated in vitro free radical formation. Mol Cell Biochem 228, 73–82 (2001). https://doi.org/10.1023/A:1013348005312

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1013348005312

Search

Navigation